What does "microdosing" a GLP-1 actually mean?

There is no FDA-approved "microdose" regimen for weight management. When programs use the term, they usually mean one of three things: staying at the standard low starting dose longer than the label's escalation schedule, prescribing smaller increments of compounded semaglutide or tirzepatide, or splitting doses for cost reasons.

A clinician can legally prescribe off the labeled schedule when they judge it appropriate for a patient — that is ordinary medical practice. What you should not accept is a program that markets microdosing as a proven protocol without telling you it sits outside the dosing the FDA reviewed.

What does approved dosing look like?

Every approved GLP-1 weight-management regimen already starts low and climbs slowly. Zepbound, per the FDA, is titrated over 4 to 20 weeks toward a maintenance dose of 5, 10, or 15 mg weekly. Semaglutide follows a similar stepwise escalation to its 2.4 mg weekly target.

That built-in ramp exists to manage the gastrointestinal side effects that cluster around dose increases. In a sense, everyone on a GLP-1 "microdoses" at the start — the question is what dose you maintain, and that decision belongs to you and your prescriber.

What does the evidence show — and not show?

The headline trial results were produced at full maintenance doses. STEP 1's 14.9% average reduction used semaglutide 2.4 mg weekly; SURMOUNT-1's 15.0%–20.9% range covered tirzepatide 5–15 mg weekly. Even SURMOUNT-1's lowest tested dose, 5 mg, is a full labeled maintenance dose — not a microdose.

Sustained low-dose regimens below the labeled targets have not been validated in comparable large trials. That does not mean a lower dose does nothing — dose-response data shows effects scale with dose — but it means nobody can honestly promise you trial-level results at a fraction of the trial dose.

Why do people consider lower doses?

Three reasons come up repeatedly: side-effect sensitivity, since gastrointestinal symptoms are the most common reason people stop treatment; cost, because lower doses can stretch supply and budgets; and smaller goals, where someone wants modest appetite support rather than maximum weight reduction.

All three are legitimate conversations to have with a clinician. The NIDDK checkpoint still applies, though: if treatment is not producing at least a 5% reduction after 12 weeks at your prescribed dose, the plan should change rather than drift.

What should you ask a microdosing program?

Use these five questions to separate careful prescribers from marketing operations:

• Who sets my dose? A licensed clinician should make the call after reviewing your history — not a standard "microdose plan" sold off the shelf.
• What exactly am I getting? Brand-name pens, or compounded medication? If compounded, which pharmacy and what oversight?
• What is the plan if it isn't working? There should be a defined checkpoint, consistent with NIDDK's 12-week guidance.
• What does each dose level cost? Get pricing for standard doses too, in case your clinician recommends escalating.
• How do I report side effects? Messaging access to the care team matters most during any dose change.

Who should skip this approach?

The class-level exclusions still apply at any dose: no use in pregnancy, and the FDA warns against tirzepatide for people with a personal or family history of medullary thyroid cancer or MEN2. A smaller dose does not make an unsuitable medication suitable.

And if you are drawn to microdosing mainly because the full-dose price is out of reach, compare pill-based programs and coaching plans first — a validated treatment you can afford beats an improvised version of one you cannot.